Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Actinogen Medical ( (AU:ACW) ) has shared an update.
Actinogen Medical has requested and been granted a trading halt in its securities on the ASX pending the release of results from an interim analysis of its XanaMIA Phase 2b/3 Alzheimer’s disease trial, conducted by an independent Data Monitoring Committee. The halt will remain in place until either the interim analysis outcome is announced to the market or trading resumes on 2 February 2026, signalling that pivotal clinical data may be imminent and potentially significant for the company’s development trajectory and investor sentiment.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an Australian biotechnology company listed on the ASX that focuses on developing therapies for neurological disorders, including Alzheimer’s disease, with its key clinical program currently centred on the XanaMIA Phase 2b/3 Alzheimer’s disease trial.
Average Trading Volume: 5,638,373
Technical Sentiment Signal: Buy
Current Market Cap: A$159.6M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.